Genital Warts Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Genital Warts market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Verrica Pharmaceuticals, Tamir Biotechnology, Novan Inc., Medicis Pharmaceuticals, Aresus Pharma, AbbVie

[Nevada, United States] - DelveInsight's "Genital Warts Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Genital Warts, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Genital Warts Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/genital-warts-condyloma-acuminatum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Genital Warts Market Report:
• The Genital Warts market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In August, 2024: Shanghai Bovax Biotechnology Co., Ltd. announced that their study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Human Papillomavirus (HPV) Recombinant Vaccine (Hansenula Polymorpha) in Chinese male subjects aged 18-45 years. The primary hypothesis in the study is the 9-valent HPV recombinant vaccine reduces the incidence of vaccine HPV types-related genital warts compared with placebo in Chinese men.
• In July, 2024: Merck Sharp & Dohme LLC announced that the purpose of their study is to to evaluate the efficacy of V503 (9-valent human papillomavirus [9vHPV] vaccine) in preventing HPV-related anogenital persistent infection, and to evaluate the safety/tolerability of V503, in Japanese males who are 16 to 26 years of age.
• In June, 2024: Shanghai Bovax Biotechnology Co., Ltd. announced that their study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .
• In April, 2024: Shanghai Bovax Biotechnology Co., Ltd. announced that their phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
• In 2023, approximately 866k incident cases of Genital Warts (Condyloma Acuminatum) existed in the 7MM. Factors contributing to the rise in incident cases of genital warts in the 7MM includes improved detection and reporting, decreased immunity, and changes in sexual behavior.
• When the incident cases of genital warts were segmented based on gender in the 7MM, a higher number of cases was observed in the females as compared to males. In 2023, approximately 459k females were found to be affected by genital warts in the 7MM, and these cases are further projected to change during the study period (2020-2034).
• In the 7MM, the United States accounted for the highest number of genital warts incident cases, totaling approximately 547k cases in 2023, and these cases are further expected to increase during the study period (2020-2034).
• In Japan, incidence of genital warts cases is the highest among people with age 18-29 years of age followed by 30 to 39 years of age and 40 and above years of age. In 2023, there were 15,731 cases among 18-29 years age group, 10,988 cases among 30-39 years age-group and 10,842 cases among 40 and above age group.
• Key Genital Warts Companies are as follows: Verrica Pharmaceuticals, Tamir Biotechnology, Novan Inc., Medicis Pharmaceuticals, Aresus Pharma, AbbVie
• Key Genital Warts Therapies are as follow: VP-102, SB207, Imiquimod, 9vHPV vaccine, Investigational, AP611074, Topical AS101, Picato, V501, Podofilox, Condylox, AP611074, Polyphenon, Ranpirnase, Viusid®, Glizigen®
• Launching multiple stage Genital Warts pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Genital Warts market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/genital-warts-condyloma-acuminatum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Genital Warts Overview:
Human papillomavirus (HPV) is a small, non-enveloped, double] stranded DNA virus. Most of the HPV-related diseases and research are focused on HPV types within the alpha group. Individual types are further classified as high-risk (e.g., HPV16 and 18) and low-risk HPV (e.g., HPV6 and 11) based on oncogenic potential.

Genital Warts Epidemiology Segmentation:
The Genital Warts market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Genital Warts Gender-specific Incident Cases
• Genital Warts Incident Cases
• Genital Warts Anatomical Location
• Genital Warts Diagnosed Cases of Episodic and Chronic

For more information about Genital Warts companies working in the treatment market, visit https://www.delveinsight.com/sample-request/genital-warts-condyloma-acuminatum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Genital Warts Market Insights
The global genital warts market was valued at approximately USD 1.4 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6-7% over the next five years. The increasing incidence of HPV infections, ongoing research into innovative treatments, and expanded vaccination coverage are the main factors driving market growth.

Genital Warts Drugs Uptake
• Imiquimod (Aldara) Imiquimod, a topical immune response modifier, is one of the most commonly prescribed treatments for genital warts. It works by stimulating the body's immune system to fight the HPV infection, leading to the regression of warts. It remains popular due to its non-invasive nature, although it can cause local irritation. The uptake of imiquimod is stable, particularly in regions where non-surgical treatments are preferred.
• Podophyllotoxin (Condylox) Podophyllotoxin is another widely used topical agent that directly targets the wart tissue, causing necrosis of the affected cells. Its efficacy and availability in various forms, such as creams and gels, make it a popular choice. However, its use is often limited by the need for precise application to avoid damage to surrounding healthy skin.
• Sinecatechins (Veregen) Derived from green tea extract, sinecatechins offer a natural, plant-based treatment for external genital warts. It is considered effective for smaller warts and has minimal side effects, though uptake is lower compared to other topical treatments due to its slower action.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/genital-warts-condyloma-acuminatum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Genital Warts Therapies and Key Companies:
• VP-102: Verrica Pharmaceuticals
• SB207: Novan
• Imiquimod: Graceway Pharmaceuticals, LLC
• 9vHPV vaccine: Merck Sharp & Dohme LLC
• Investigational: Novartis Pharmaceuticals
• AP611074: Vaxart
• Topical AS101: BioMAS Ltd
• Picato: LEO Pharma
• V501: Merck Sharp & Dohme LLC
• Podofilox, Condylox: Dermax SA
• AP611074: Anaconda Pharma
• Polyphenon: MediGene
• Ranpirnase; Tamir Biotechnology, Inc.
• Viusid®, Glizigen®: Catalysis SL

Genital Warts Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Genital Warts.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/genital-warts-condyloma-acuminatum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Genital Warts Market Drivers:
• Increasing Awareness and Education
• HPV Vaccination Programs
• Advances in Treatment Options
• Rising Prevalence of HPV Infections

Genital Warts Market Barriers:
• Social Stigma
• High Cost of Vaccination
• Side Effects of Treatments
• Lack of Awareness in Developing Regions

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/genital-warts-condyloma-acuminatum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Genital Warts Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Genital Warts Companies: Verrica Pharmaceuticals, Tamir Biotechnology, Novan Inc., Medicis Pharmaceuticals, Aresus Pharma, AbbVie
• Key Genital Warts Therapies: VP-102, SB207, Imiquimod, 9vHPV vaccine, Investigational, AP611074, Topical AS101, Picato, V501, Podofilox, Condylox, AP611074, Polyphenon, Ranpirnase, Viusid®, Glizigen®
• Genital Warts Therapeutic Assessment: Current marketed and emerging therapies
• Genital Warts Market Dynamics: Genital Warts Market drivers and Genital Warts barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Genital Warts Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Genital Warts market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/genital-warts-condyloma-acuminatum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Genital Warts Market Overview at a Glance
4 Executive Summary of Genital Warts
5 Disease Background and Overview: Genital Warts
6 Treatment and Management
7 Vaccines
8 Guidelines
9 Epidemiology and Patient Population
10 Patient Journey
11 Marketed Therapies
12 Emerging Drug
13 Genital Warts: Seven Major Market
14 Key Opinion Leaders' Views
15 SWOT Analysis
16 Unmet Needs
17 Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.